U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06807359) titled 'A Phase I/II Study of Photodynamic Therapy Treatment of Primary Localized Prostate Cancer' on Jan. 29.
Brief Summary: The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE(R), together with verteporfin for injection (VFI) as photosensitizer, for the treatment of primary localized prostate cancer.
The study will be divided into two parts, with Phase I, dose-escalation, to study safety and establish an effective light dose, followed by Phase II, cohort expansion, to evaluate clinical efficacy and confirm safety/tolerability. The subjects wil...